



Renal Solutions – Press Kit

Fact Sheet

Founded

August 1, 2000

Headquarters

Renal Solutions, Inc.

Phone: (724) 772-6900

770 Commonwealth Drive
Suite 101

Fax: (724) 772-6925

Warrendale, PA 15086

www.renalsolutionsinc.com

Profile

Renal Solutions, a wholly-owned subsidiary of Fresenius Medical Care, is leading the advancement of sorbent technology for improved renal replacement therapy. Through the development of innovative products and services, Renal Solutions is driving the movement toward true portability and future wearable technology by maximizing the flexibility, convenience and quality of sorbent therapy.

SORB™ Technology, Inc. has been making sorbent hemodialysis systems and disposable cartridges under different names and ownerships since 1977. Based in Oklahoma City, SORB Technology merged with Renal Solutions in 2001. Visit www.sorb.net for information regarding sorbent dialysis with the REDY 2000 and ordering REDY 2000 disposable products and spare parts.

Products and Technology

Renal Solutions' patented, innovative sorbent cartridges require only 6 liters of potable tap water, the lowest volume option available, to provide highly pure dialysate for an entire treatment. Sorbent Management for Advanced Renal Replacement Therapy (SMARRT™) is a proven technology, backed by over 6 million clinical treatments. This important technology provides freedom from complex water treatment systems, opening new treatment options across chronic and acute dialysis settings. SMARRT will ultimately drive renal replacement therapy toward true portability and future wearable technology.

Management

| | |
|---------------------------|---|
| Peter M. DeComo | Co-founder and CEO |
| Derrick L. Latos, MD MACP | Medical Director |
| John J. Maholtz | Senior Vice President, Engineering & Operations |
| R. Preston Thompson | Senior Vice President, SORB™ Technology |
| Dave Updyke | Senior Vice President, Technical Marketing |
| David Vanella | Senior Vice President, QA/RA |



Press Release

Renal Solutions Adds Two New Members to Medical Advisory Board: Dr. Jose Diaz-Buxo and Dr. Todd Ing

WARRENDALE, PA June 17, 2008 – Renal Solutions, Inc (RSI), a wholly-owned subsidiary of Fresenius Medical Care, and the leader in the advancement of sorbent technology for improved renal replacement therapy, announced today the addition of two members to its Medical Advisory Board, Jose Diaz-Buxo, M.D., FACP and Todd Ing, M.D.

Dr. Diaz-Buxo is Chief Medical Officer and Senior Vice President, Renal Therapies Group, Fresenius Medical Care North America. He is also Senior Advisor for Global Home Therapies, Fresenius Medical Care. He is known for his development of continuous cyclic peritoneal dialysis and various PD cyclers, his development of external occlusion for PD disconnect systems, and early identification of acute renal failure from contrast material injection. Dr. Diaz-Buxo has been a physician at the Mayo Clinic, the Carolinas Medical Center, the University of North Carolina, Chapel Hill, and has served on multiple editorial and review boards, including *Clinical Nephrology*, *Peritoneal Dialysis International*, *Kidney International*, and *American Journal of Kidney Diseases*. He has published more than 270 peer-reviewed papers, editorials and book chapters. He has received awards from the American Kidney Fund, the National Kidney Foundation and been listed in the Best Doctors in America and Who's Who in Medicine.

Dr. Ing is currently courtesy staff physician in the Department of Medicine at the Veterans Affairs Hospital in Hines, IL as well as Professor Emeritus of Medicine at Loyola University Chicago, Stritch School of Medicine. He has provided renal care to veterans for more than 25 years and for years has published articles and books and organized educational seminars for patients and healthcare professionals alike. He has been on the editorial boards for *Kidney*, *Hong Kong Journal of Nephrology*, *Hemodialysis International* and *Peritoneal Dialysis International*. Dr. Ing has authored more than 250 publications in the area of dialysis with emphasis on isolated ultrafiltration, complications of dialysis, dialysate composition and peritoneal dialysis (PD). He is also co-editor of the *Handbook of Dialysis* which is widely used around the world. The American Association of Kidney Patients (AAKP) recently presented the *Medal of Excellence Award* to Dr. Ing.

“We’re excited to have such distinguished additions to our Medical Advisory Board,” said Peter DeComo, President and CEO of Renal Solutions. “The strength of our technology lies in its ability to be relevant and valuable to the medical community – Dr. Diaz-Buxo and Dr. Ing bring us the quality leadership that will best inform our approach.”

(more)

Renal Solutions Adds Two New Members to Medical Advisory Board: Dr. Jose Diaz-Buxo and Dr. Todd Ing

- page 2 -

RSI is the leader in advancing sorbent technology for renal replacement therapy in acute or chronic dialysis settings. The company's patented, innovative sorbent cartridges require just 6 liters of potable tap water, the lowest volume option available, to provide highly pure dialysate for up to 8 hours of therapy.

About Renal Solutions, Inc

Renal Solutions, a wholly-owned subsidiary of Fresenius Medical Care, is the leader in the advancement of sorbent therapy for improved renal replacement therapy. Renal Solutions is driving the movement toward portability and future wearability by maximizing the value of sorbent technology for a range of revolutionary products and services. SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) is the only technology that regenerates used dialysate into fresh, highly pure dialysate using 6L of potable tap water. SMARRT technology provides the sorbent-driven flexibility, convenience and quality benefits that translate into more treatment options.

For more information about Renal Solutions visit the Company's website at www.renalsolutionsinc.com.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company's products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Contact:

Media Inquiries:
Jennifer Bannan
Zero to Five, LLC
(412) 580-3675
jen@0to5.com

Commercial Inquiries:
Sue Bentley
Marketing Director, Renal Solutions, Inc.
(724) 772-6900 ext. 109
sue.bentley@renalsolutionsinc.com

Press Release

Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care

WARRENDALE, PA November 29, 2007 – Renal Solutions, Inc (RSI) announced today that the Company has been acquired by Fresenius Medical Care AG & Co. KGaA. RSI will continue operations as a wholly owned subsidiary of Fresenius Medical Care, the largest integrated global provider of dialysis products and services. Peter DeComo will continue to lead RSI operations in Warrendale, PA and Oklahoma City, OK.

Renal Solutions is the innovator in the field of sorbent dialysis therapy. The Company's sorbent technology is based on a more than 35-year history of proven dialysis therapy and enables flexible treatment options using only 6 liters of drinking water. RSI holds a number of key patents and other intellectual property related to sorbent dialysis therapy and has recently launched its Sorbent Management for Advanced Renal Replacement Therapy (SMARRT™) platform.

SMARRT therapy utilizes a gentle, patient-driven technology backed by over 6 million treatments. It enables short, standard or extended duration hemodialysis therapy using only 6 liters of drinking water without requiring the use of a water treatment system. The small dialysate quantity made possible by sorbent technology provides an inherent volume safety not possible with conventional hemodialysis technology. At the same time, it creates a dialysate flow rate of up to 400 ml/min., enabling the provision of highly effective dialysis. Advanced sorbent cartridges contain specialized sorbent compounds that regenerate fresh, high purity dialysate, eliminating the need for complex and costly water purification systems.

"This acquisition validates the strategic importance of sorbent technology to the dialysis field," said Peter DeComo, President and CEO of Renal Solutions. "The combination of Renal Solutions and Fresenius Medical Care, the global leader in dialysis products and services, will maximize the value of sorbent therapy through rapid development of innovative products and services that would have been difficult to achieve as a small independent company," he continued. "The convergence of our respective resources will enhance the prospects for true innovative approaches, including portability and wearability, to further improve the service to patients requiring dialysis therapy worldwide."

RSI is currently commercializing the Allient® Sorbent Hemodialysis System for chronic and acute hemodialysis applications. The Allient System will be the first dialysis system to bring SMARRT technology to the market, opening new treatment options to dialysis professionals and patients.

(more)

Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care

--page 2--

The current RSI home use clinical study featuring the Allient System and sorbent technology will continue enrollment at multiple sites. The trial is designed to demonstrate patient ability to self-administer hemodialysis in the home using the FDA cleared system. In this research study, 25 dialysis participants will self-administer extended duration dialysis in the home.

Morgan Stanley served as advisor to Renal Solutions for the transaction.

About Renal Solutions, Inc

Renal Solutions, Inc., a medical device and healthcare service company, is commercializing the Allient® Sorbent Hemodialysis System, a revolutionary technology/service solution for the chronic and acute dialysis market. The Allient System, brings SMARRT (Sorbent Management for Advanced Renal Replacement Therapy) therapy to the dialysis field, opening new treatment options to dialysis professionals and patients by virtue of its ability to provide short, standard or extended duration hemodialysis therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous clinical studies have shown that an increased cumulative dialysis dose results in better patient outcomes. The Allient System provides the increased dose advantage without the need for an independent water system or large volumes of sterile fluid. This translates into increased flexibility and convenience benefits. For more information about Renal Solutions visit the Company's website at www.renalsolutionsinc.com.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company's products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Contact:

Media Inquiries:
Jennifer Bannan
Zer0 to Five, LLC
(412) 580-3675
jen@0to5.com

Commercial Inquiries:
Sue Bentley
Marketing Director, Renal Solutions, Inc.
(724) 772-6900 ext. 109 sue.bentley@renalsolutionsinc.com



Frequently Asked Questions...

Is sorbent therapy new?

Sorbent technology was developed from a NASA funded project for removing toxins from waste water for the space program. It has a 35-year and is backed by over six million treatments. Sorbent cartridges have been recently redesigned and can now regenerate dialysate at flow rates of up to 400 ml/min (SORB™ + cartridges) and for treatment times as long as 8 hours (SORB™ HD cartridges).

What is the quality of the dialysate produced by sorbent cartridges?

Sorbent cartridges provide near ultrapure dialysate (< 1 cfu/ml and < 0.3 EU/ml), exceeding ANSI/AMMI standards and conventional single-pass technology.

Sorbent cartridges have been shown to increasingly purify dialysate throughout a treatment, resulting in near ultrapure final dialysate with mean bacterial levels of < 1cfu/ml and endotoxin levels < 0.3 EU/ml. These levels exceed AMMI/ANSI and ISO standards for dialysate purity. The sorbent cartridge provides near ultrapure final dialysate, not dialysate made with ultrapure water as is defined as a highly desirable standard.

Following is a summary table highlighting the purity of the dialysate:

| Contaminant | AMMI/ANSI Standard | Sorbent Cartridge | Ultrapure Standard |
|---|--------------------|-------------------|--------------------|
| Bacterial Cell Count | 200 CFU per ml | < 1 CFU per ml | 0.1 CFU per ml |
| Endotoxin Level | 2 EU per ml | 0.3 EU per ml | .03 EU per ml |
| Patient Dialysate Volume Exposure/4 hour Tx | 120 Liters | 6 Liters | NA |

Is clearance sacrificed with sorbent therapy because of the small volume of dialysate that is available?

While the volume relationship is an important safety advantage for sorbent therapy, it does not mean that clearance is sacrificed in any way. Each 6-liter bath provides the equivalent of 100 liters or more of highly pure dialysate that is tailored to the patient's

individual situation and provides the clearances needed without requiring high blood flows to make up for low dialysate flows. What this means clinically is that at the same dialysate and blood flow rate and with the same dialyzer, sorbent dialysis will produce the same efficiency of dialysis as any standard single-pass hemodialysis system.



Management Team



Peter M. DeComo, CEO

Pete DeComo is the CEO of Renal Solutions, Inc. a wholly-owned subsidiary of Fresenius Medical Care. Mr. DeComo, a co-founder, served as the Chairman and CEO of Renal Solutions subsequent to the acquisition and merger. He was previously the COO of HemoTherapies Inc. where he led the commercialization of the only FDA-cleared Liver Dialysis System. Mr. DeComo was Senior Vice President of the Specialty Pharmacy Division for Olsten Health Services, now Accredo, a \$600 million specialty pharmacy provider. Prior to joining Olsten, Mr. DeComo held numerous senior level positions in the health care industry.

Mr. DeComo currently serves as a member of Congressman Jason Altmire's Health Advisory Committee and is a director on the boards of the National Kidney Foundation of the Alleghenies, ThermalTherapeutic Systems, Inc., ClearCount Medical Solutions, Inc., Pittsburgh Life Sciences Greenhouse and the Pittsburgh Technology Council. He has also served as a director on the board of Curative Health Services (NASDAQ: CURE).

Mr. DeComo is the recipient of numerous "Entrepreneur of the Year" awards having been recognized by Ernst & Young in 2008, Pittsburgh Venture Capital Association in 2007, and the Carnegie Science Center in 2005. Mr. DeComo received his MS and BS degrees in Healthcare/Business Management from the University of Pittsburgh.



Derrick L. Latos, MD MACP, Medical Director

Derrick L. Latos, MD, MACP is Medical Director of Renal Solutions and also serves as Chairman of the Medical Advisory Board. He is a Clinical Professor of Medicine at the West Virginia University School of Medicine and Medical Director for Wheeling Renal Care, LLC. in Wheeling, W.V. He is past president of the Forum of ESRD Networks and of the Renal Physicians Association. Dr. Latos also serves on the Editorial Advisory Board of *Nephrology News and Issues* and on the Board of the National Kidney Foundation of the Alleghenies. He has been widely published in peer-reviewed literature on numerous nephrology topics.



**John J. Maholtz,
Senior Vice President, Engineering & Operations**

Mr. Maholtz joined Renal Solutions in June of 2003 as Senior Vice President of Engineering and Operations. Immediately prior to joining Renal Solutions he served as Director of Global Market Operations for Free Markets, Inc., a publicly traded company based in Pittsburgh, PA. He was responsible for services in North America, Europe and Asia. Prior to joining Free Markets, he served as Vice President of Global Marketing and Distribution for Oberg Industries, a privately held tool and die manufacturer. Before Oberg, Mr. Maholtz was with Respironics Inc. as Manager of Engineering. In that capacity, he was responsible for new product development and sustaining engineering. In that role he led the team that won the Society of Plastics Engineers 1995 "Consumer Product of the Year Award." Mr. Maholtz also held senior engineering positions at Bayer Corporation and Amp Incorporated. Mr. Maholtz holds an MS Degree in Industrial Administration from Carnegie Mellon and a BS in Mechanical Engineering from the Pennsylvania State University.



**R. Preston Thompson, Senior Vice President, SORB™
Technology, Inc.**

Mr. Thompson is Senior Vice President and General Manager of SORB™ Technology, Inc. He has over 25 years experience in sorbent regenerative dialysis disposables operations, holding previous positions as operations director, production manager, chemical R&D manager, technical buyer, and quality control supervisor. Mr. Thompson was the lead chemical engineer for the revised development of the sorbent cartridges in the early 1980s and has led the recent development of the Company's advanced sorbent cartridge series. Mr. Thompson has been awarded 3 patents related to disposable devices in the dialysis field. Mr. Thompson holds an MBA in general management, with a BS in management and a BS in chemistry.



Dave Updyke, Senior Vice President, Technical Marketing

Mr. Updyke is Senior Vice President of Technical Marketing for Renal Solutions, where he is responsible for overseeing the development of specifications for sorbent products and technical innovations. Prior to his current role, Mr. Updyke served in numerous senior-level positions at Fresenius Medical Care for over 20 years. Most recently, he served as the Vice President of Future Technology Implementation, where he was responsible for determining the direction of sorbent technology within the Fresenius family of products. As Vice President of Dialysis Service Technology, he was responsible for New Therapy Support, which included the nationwide roll-out of the online clearance/adequacy monitoring, monthly access flow monitoring, and the Urea Kinetic Modeling programs. In this position he was also responsible for overseeing operations of NephroMed Distribution, a start-up company with \$50 million in annual sales, as well as the Fresenius Medical Care Pharmacy Services, Risk Management Department, and Fresenius US Vascular Services.



David J. Vanella, Senior Vice President of Quality Assurance and Regulatory Affairs

David J. Vanella joined Renal Solutions in April 2005, where he oversees regulatory affairs and quality initiatives. Prior to this position, Mr. Vanella served in numerous leadership and regulatory positions at Respironics (now Phillips) during his 13-year tenure. At Respironics he served in the role of Director of Quality Assurance for the \$400 million Homecare Division where he was responsible for all compliance activities for manufacturing, distribution and corporate facilities. Prior to this role he served as Manager of Regulatory Affairs and was responsible for worldwide regulatory product market approvals., Mr. Vanella was successful in obtaining over 25 product approvals including the C-Flex CPAP system that revolutionized CPAP therapy for treating Obstructive Sleep Apnea. Mr. Vanella currently serves as the medical device expert on the Safety Advisory Board for SRI, an accredited registrar that issues quality, medical device, and various quality system registrations. Mr. Vanella holds an MS degree in Business Administration from Duquesne University and a BS in Electrical Engineering from the University of Pittsburgh.



Medical Advisory Board

Derrick L. Latos, MD, MACP

Derrick L. Latos, MD, MACP, is Chairman of the Medical Advisory Board and also serves as Medical Director of Renal Solutions. He is a Clinical Professor of Medicine at the West Virginia University School of Medicine and Medical Director for Wheeling Renal Care, LLC. in Wheeling, W.V. He is past president of the Forum of ESRD Networks and of the Renal Physicians Association. Dr. Latos also serves on the Editorial Advisory Board of *Nephrology News and Issues* and on the Board of the National Kidney Foundation of the Alleghenies. He has been widely published in peer-reviewed literature on numerous nephrology topics.

John Agar, MBBS, FRCP(Lond), FRACP

John Agar, MBBS, FRCP(Lond), FRACP, a renowned nocturnal home hemodialysis advocate, is Director of Nephrology and Chief of Service Medicine at Barwon Health in Geelong, Australia. Currently, he is the senior transplant physician to the Transplant Service at St. Vincent's Hospital, Melbourne, and is a Clinical Associate Professor of Medicine at the University of Melbourne. An enthusiastic home hemodialysis supporter, 40% of his dialysis patient population dialyzes at home with 25% of his hemodialysis patients using nocturnal home hemodialysis. Dr. Agar has been widely published in peer-reviewed literature on the medical and economic benefits of nocturnal home hemodialysis and has been a recognized leader in the expansion of this innovative therapy in Australia.

Stephen R. Ash, MD, FACP

Stephen R. Ash, MD, FACP, brings extensive experience in the fields of sorbent-based dialysis systems, peritoneal and hemodialysis to the board. Dr. Ash is co-inventor of the Allient® Sorbent Hemodialysis System and co-founder of Renal Solutions. He serves as Chairman of the Board of HemoCleanse, Inc. and Ash Access Technology, Inc. Dr. Ash is also Director of the Dialysis Center for Greater Lafayette and a practicing nephrologist at Arnett Clinic in Lafayette, Indiana. He has been awarded over 30 patents for various dialysis devices and therapeutic instruments, has published over 100 peer-reviewed articles, and is author of 12 textbook chapters regarding hemodialysis and peritoneal dialysis.

Jose Diaz-Buxo, MD, FACP

Dr. Diaz-Buxo is Chief Medical Officer and Senior Vice President, Renal Therapies Group, Fresenius Medical Care North America. He is also Senior Advisor for Global Home Therapies, Fresenius Medical Care. He is known for his development of continuous cyclic peritoneal dialysis and various PD cyclers, his development of external occlusion for PD disconnect systems, and early identification of acute renal failure from contrast material injection. Dr. Diaz-Buxo has been a physician at the Mayo Clinic, the Carolinas Medical Center, the University of North Carolina, Chapel Hill, and has served on multiple editorial and review boards, including *Clinical Nephrology*, *Peritoneal Dialysis International*, *Kidney International*, and *American Journal of Kidney Diseases*. He has published more than 270 peer-reviewed papers, editorials and book chapters. He has received awards from the American Kidney Fund, the National Kidney Foundation and been listed in the Best Doctors in America and Who's Who in Medicine.

David Humes, MD

David Humes, MD is an international authority in the areas of acute renal failure, stem cell biology, and tissue engineering. He is President of Innovative BioTherapies, Inc. and a professor of internal medicine at the University of Michigan, Ann Arbor. Dr Humes is the scientific founder of Nephron and RenalMed Biologic, Inc. He is also a member of the editorial boards of five scientific journals, has published approximately 200 scientific papers, and edited numerous textbooks. Dr. Humes has more than 70 U.S. and international patents issued or pending. Among the many awards bestowed on him is the President's Award from the National Kidney Foundation and the A.N. Richards Distinguished Achievement Award in Nephrology.

Todd Ing, M.D.

Dr. Ing has previously worked as a staff physician in the Department of Medicine at the Veterans Affairs Hospital in Hines, IL. He has provided renal care to veterans for more than 25 years and has organized educational seminars for patients and healthcare professionals alike. He has been on the editorial boards for the *International Journal of Artificial Organs*, *Artificial Organs*, *Transactions of the American Society for Artificial Internal Organs*, *Kidney*, *Journal of American Paraplegia Society*, *Hemodialysis International* and *Peritoneal Dialysis International*. Dr. Ing has authored more than 250 publications in the area of dialysis with emphasis on isolated ultrafiltration, complications of dialysis, dialysate composition and peritoneal dialysis. He is also co-editor of the Handbook of Dialysis which is widely used around the world. He was presented the National Torchbearer Award by the American Kidney Fund in 2005. The American Association of Kidney Patients (AAKP) recently presented the *Medal of Excellence Award* to Dr. Ing.

Robert S. Lockridge Jr., MD

Robert S. Lockridge Jr., MD is a highly acclaimed innovator in the effort to provide more frequent, long-duration dialysis in the United States. Dr. Lockridge is Medical Director of UVA-Lynchburg Dialysis Facility and a partner of Lynchburg Nephrology Physicians in Lynchburg, VA, widely recognized as one of the leading and most successful nocturnal home hemodialysis programs, founded in 1997. Dr. Lockridge is a leader in advocacy initiatives, having played an instrumental role in the introduction and lobbying for legislation supporting enhanced home dialysis reimbursement. He is active in the National Institutes of Health (NIH) study on long-duration home hemodialysis. He also serves as a Clinical Associate Professor of Internal Medicine at the University of Virginia School Health System.

Amit Sharma, MD, FACP, FASN

Amit Sharma, MD, FACP, FASN, has extensive experience conducting primary research and as a Principal Investigator for numerous clinical trials in the field of nephrology and hypertension. He is Director of Clinical Research at Boise Kidney and Hypertension Institute in Meridian, Idaho and served as Assistant Clinical Professor of Medicine at the University of California, San Diego, as well as Assistant Professor of Medicine at the Uniformed Services University of Health Sciences in Bethesda, Maryland. From 2001-2005, he was the Director of the Dialysis Unit and of the Chronic Kidney Disease Clinic at the Naval Medical Center, San Diego. Dr. Sharma received his medical degree from Louisiana State University Medical Center-New Orleans. He also serves as a relevance reviewer for the American Board of Internal Medicine for Nephrology, is on the editorial board of *Cardiology Reviews*, and serves on national committees for ASN and NKF.